



Jupiter Life Line Hospitals Limited

6th October, 2023

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Outcome of the Board Meeting held on Friday, 6th October ,2023

Dear Sir/Madam,

In furtherance to our intimation dated 30th September, 2023, this is to inform you that pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its Meeting held today, i.e., 6th October, 2023 has considered and approved the Unaudited Financial Results of the Company, for the quarter ended 30th June, 2023 along with the Limited Review Report and noted the Independent Auditors' Review Reports with unmodified opinions on the said quarterly financial results.

A copy of the said results along with the Limited Review Report issued by the Statutory Auditors of the company are enclosed herewith for your record.

The Board Meeting commenced at 3:00 P.M and concluded at 4.30 P.M.

You are requested to kindly take the afore mentioned on record and oblige.

Yours faithfully,

For JUPITER LIFE LINE HOSPITALS LIMITED,

SUMA VINAYAK
UPPARATTI

Digitally signed by SUMA
VINAYAK UPPARATTI
Date: 2023.10.06 16:38:33
+05'30'

Suma Upparatti
Company Secretary & Compliance Officer
Membership No: - F8986

Independent Auditor's Review Report on standalone unaudited quarterly financial results of Jupiter Life Line Hospitals Limited

TO THE BOARD OF DIRECTORS OF JUPITER LIFE LINE HOSPITALS LIMITED

We have reviewed the accompanying statement of unaudited financial results of Jupiter Life Line Hospitals Limited for the period ended 30th June 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") [prescribed u/s 133 of the Companies Act 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Aswin P. Malde & Co.
Chartered Accountants
FRN 100725W

Aswin Popatlal Malde
Digitally signed by
Aswin Popatlal Malde
Date: 2023.10.06
16:37:16 +05'30'

Aswin P. Malde
Proprietor
M.No.032662
Date: 06 October 2023, Mumbai
UDIN : 23032662BGUTCD8774

JUPITER LIFE LINE HOSPITALS LIMITED
CIN: U85100MH2002PLC137908

STATEMENT OF UNAUDITED STADALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(Rs in Millions)

Particulars	Unaudited	Unaudited	Unaudited	Audited
	quarter ended	quarter ended	quarter ended	year ended
	30th June	31st March	30th June	31st March
	2023	2023	2022	2023
Revenue from Operations	2,078.73	2,104.73	1,789.23	7,873.22
Other income	67.92	65.62	19.34	132.95
TOTAL INCOME	2,146.65	2,170.35	1,808.57	8,006.17
EXPENSES				
Purchases of Stock-in-Trade	366.46	351.24	314.18	1,371.30
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(12.54)	13.08	(17.56)	(22.30)
Employee benefits expense	376.15	357.57	304.77	1,336.24
Finance costs	82.09	73.91	65.09	277.12
Depreciation and amortisation expense	77.54	72.52	70.31	286.08
Professional Fees	503.85	486.09	404.10	1,812.64
Other expenses	333.45	376.50	295.16	1,335.02
TOTAL EXPENSES	1,727.00	1,730.91	1,436.05	6,396.10
Profit before exceptional items and tax	419.65	439.44	372.52	1,610.07
Exceptional items [net credit/ (charge)]	(13.60)	(21.25)	-	(21.25)
Profit before tax	406.05	418.19	372.52	1,588.82
Tax expenses				
Current tax	102.08	155.54	128.24	556.86
Adjustments in respect of current income tax of previous year	-	-	(0.39)	4.32
MAT Credit Entitlement	-	-	(128.24)	(47.54)



Jupiter Life Line Hospitals Limited

Deferred tax credit/(charge)	(0.43)	(4.83)	1.30	3.04
PROFIT FOR THE PERIOD (A)	304.40	267.48	371.61	1,072.14
Other comprehensive income				
Other comprehensive income for the period (b)	21.25	6.67	-	6.67
Total comprehensive income for the period (a+b)	325.65	274.15	371.61	1,078.81
Paid up Equity Share Capital (Face value Re. 10 per share)	565.18	565.18	508.67	565.18
Other Equity	4,410.71	3,817.06	3,023.44	4,085.06
Earnings per equity share (Face value of Re. 10 each)				
Basic (in Rs.)	5.76	5.23	7.31	20.58
Diluted (in Rs.)	5.76	4.86	7.31	19.11

NOTES TO STANDALONE FINANCIAL RESULTS:

- The standalone financial information of Jupiter Life Line Hospitals Limited (“the Company”) for the three months ended June 30,2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 6,2023. The statutory auditors, Aswin P. Malde & Co have expressed an unmodified review conclusion on the financial results for the three months ended June 30,2023
- The standalone financial results for the three months ended March31,2023 are the balancing figures between the audited figures of full financial year and audited year to date standalone figures for the nine month ended December 31,2022.
- The Company has not made provision for Employee Benefit Expenses during the quarter.
- The Group's management team who are the Chief Operating Decision Maker (CODM) regularly reviews the operating results to make decisions about resource allocation and performance assessment. The Group operates in one business and geographical segment i.e., healthcare services in India and all the non-current assets held by the Group are located in India. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements. The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.
- Subsequent to the quarter ended June 30, 2023, the Company has completed its Fresh initial public offer ("IPO") of 90,47,469 equity shares of face value of INR 10 each at an issue price of INR 735 per share (including share premium of INR 725 per share). This includes Pre-IPO Placement of 16,73,469 shares



Jupiter Life Line Hospitals Limited

The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f September 18, 2023.

6. Previous period figures have been regrouped/ reclassified to conform the current period classification wherever required.
7. The aforesaid financial results are also available of company's website (www.jupiterhospital.com)

For and on behalf of the Board of Directors of Jupiter Life Line Hospitals Limited

ANKIT A
THAKKER

Digitally signed by ANKIT A
THAKKER
Date: 2023.10.06 16:11:44
+05'30'

Dr Ankit A. Thakker
Executive Director and CEO
DIN: 02874715
October 6, 2023
Mumbai

Regd. Office:
1004, 10th Floor, 360 Degree Business Park,
Maharana Pratap Chowk, L.B.S. Marg,
Mulund (W), Mumbai - 400 080.

CIN: U85100MH2002PLC137908
GST No: 27AABCJ19821ZN
Email: info@jupiterhospital.com
Web: www.jupiterhospital.com

Thane:
Corporate Office: Eastern Express
Highway, Thane (W) 400 601.
☎ 022 2172 5585

Pune:
Baner, Pune 411 045.
☎ 020 2799 2211

Independent Auditor's Review Report on consolidated unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF JUPITER LIFE LINE HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Jupiter Life Line Hospitals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30th June 2023 , being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30th June 2023, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors , has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind AS 34") [prescribed u/s 133 of the Companies Act 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
Parent :
Jupiter Life Line Hospitals Limited
Subsidiaries :
Jupiter Hospital Projects Private Limited

Medulla Healthcare Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements / financial information / financial results of 'Jupiter Hospital Projects Private Limited' one of the subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total assets of Rs.2950.66 million as at 30th June 2023 and total revenues of Rs. 354.27 million, total net profit/(loss) after tax of Rs.240.85 million and total comprehensive income / loss of Rs.240.85 million , for the quarter ended 30th June 2023, and cash flows (net) of Rs. 0.85 million for the period from 1st April 2023 to 30th June 2023, as considered in the consolidated unaudited financial results. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Aswin P. Malde & Co.

Chartered Accountants

F.R.N. 100725W

Aswin
Popatlal
Malde

Digitally signed by
Aswin Popatlal Malde
Date: 2023.10.06
16:18:30 +05'30'

Aswin P. Malde

Proprietor

M.No.032662

Date 06 October 6, 2023, Mumbai

UDIN : 23032662BGUTCE9225



Jupiter Life Line Hospitals Limited

JUPITER LIFE LINE HOSPITALS LIMITED
CIN: U85100MH2002PLC137908

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(Rs in Millions)

Particulars	Unaudited quarter ended	Unaudited quarter ended	Unaudited quarter ended	Audited year ended
	30th June	31st March	30th June	31st March
	2023	2023	2022	2023
Revenue from Operations	2,432.22	2,423.03	2,005.62	8,925.43
Other income	50.08	34.84	20.00	104.20
TOTAL INCOME	2,482.30	2,457.87	2,025.62	9,029.63
EXPENSES				
Purchases of Stock-in-Trade	441.07	419.20	361.63	1,608.57
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(17.03)	17.49	(27.14)	(36.76)
Employee benefits expense	451.08	411.70	352.62	1,556.36
Finance costs	121.60	109.37	100.12	422.73
Depreciation and amortisation expense	107.23	99.76	92.96	385.55
Professional Fees	619.36	852.02	481.01	2,178.77
Other expenses	407.78	206.80	344.58	1,605.29
TOTAL EXPENSES	2,131.09	2,116.34	1,705.78	7,720.51
Profit before exceptional items and tax	351.21	341.53	319.84	1,309.12
Exceptional items [net credit/ (charge)]	(13.60)	(22.04)	(0.06)	(22.04)
Profit before tax	337.61	319.49	319.78	1,287.08
Tax expenses	(202.36)	161.99	15.32	558.03
Current tax	102.08	155.54	128.24	556.86
Adjustments in respect of current income tax of previous year	-	(0.00)	(0.39)	4.32
MAT Credit Entitlement	-	(0.00)	(128.24)	(47.55)
Deferred tax credit/(charge)	(304.44)	6.45	15.71	44.40



Jupiter Life Line Hospitals Limited

PROFIT FOR THE PERIOD (A)	539.97	157.50	304.46	729.05
Other comprehensive income for the period (b)	21.25	2.02	-	2.01
Total comprehensive income for the period (a+b)	561.22	159.52	304.46	731.06
Paid up Equity Share Capital (Face value Re. 10 per share)	565.18	565.18	508.67	565.18
Other Equity	3,635.15	3,073.92	2,551.92	3,073.92
Earnings per equity share (Face value of Re. 10 each)				
Basic (in Rs.)	9.93	3.04	5.99	13.95
Diluted (in Rs.)	9.93	2.83	5.99	12.95

NOTES TO CONSOLIDATED FINANCIAL RESULTS:

- The Consolidated financial information of Jupiter Life Line Hospitals Limited (“the Company”) for the three months ended June 30,2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on October 6,2023. The statutory auditors, Aswin P. Malde & Co have expressed an unmodified review conclusion on the financial results for the three months ended June 30,2023.
- As per the Companies Act, 2013 a – “subsidiary company” or “subsidiary”, in relation to any other company (that is to say the holding company), means a company in which the holding company—
 - controls the composition of the Board of Directors; or
 - exercises or controls more than one-half of the total share capital either at its own or together with one or more of its subsidiary companies.

The entities considered in the Limited Review financial statements are listed below:

Name of the company	Country of Incorporation	Proportion of ownership interest
Jupiter Hospitals Projects Private Limited	India	94.50%
Medulla Healthcare Private Limited	India	100.00%

In case of non-body corporate (partnership firms), consolidation is done on the net income basis [share of profit/(loss)], reflected in the head other income in consolidated statement of profit & loss

The non-body corporates which are considered on net income basis are listed below:

Name of the entity	Country of Incorporation	Proportion of ownership interest
Jupiter Pharmacy	India	95%
Katyayini Hospitality	India	95%
E Flow Solutions	India	75%



Jupiter Life Line Hospitals Limited

Jupiter Gait Lab	India	51%
------------------	-------	-----

3. The Consolidated financial results for the three months ended March31,2023 are the balancing figures between the audited Consolidated figures of full financial year and audited year to date Consolidated figures for the nine months ended December 31,2022.
4. The Company has not made provision for Employee Benefit Expenses during the quarter.
5. The Group's management team who are the Chief Operating Decision Maker (CODM) regularly reviews the operating results to make decisions about resource allocation and performance assessment. The Group operates in one business and geographical segment i.e., healthcare services in India and all the non-current assets held by the Group are located in India. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information with respect to the single reportable segment, other than those already provided in financial statements. The Company is not required to disclose separately segment reporting as regards Hotel division in financial statement as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.
6. Subsequent to the quarter ended June 30, 2023, the Company has completed its Fresh initial public offer ("IPO") of 90,47,469 equity shares of face value of INR 10 each at an issue price of INR 735 per share (including share premium of INR 725 per share). This includes Pre-IPO Placement of 16,73,469 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f September 18, 2023.
7. Previous period figures have been regrouped/ reclassified to conform the current period classification wherever required.
8. The aforesaid financial results are also available of company's website (www.jupiterhospital.com)

For and on behalf of the Board of Directors of Jupiter Life Line Hospitals Limited

ANKIT A THAKKER
Digitally signed by
ANKIT A THAKKER
Date: 2023.10.06
16:11:16 +05'30'

Dr Ankit A. Thakker
Executive Director and CEO
DIN: 02874715
October 6, 2023
Mumbai